1
|
Hao W, Zhang Q, Ma Y, Ding Y, Zhao C, Tian C. Mechanism and application of HDAC inhibitors in the treatment of hepatocellular carcinoma. J Mol Med (Berl) 2025; 103:469-484. [PMID: 40131444 DOI: 10.1007/s00109-025-02532-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2024] [Revised: 01/02/2025] [Accepted: 03/14/2025] [Indexed: 03/27/2025]
Abstract
Hepatoma is the sixth most malignant tumor in the world and the second leading cause of cancer death. Among the types of hepatoma, hepatocellular carcinoma (HCC) is the most important pathological type. For patients with early-stage HCC, the curative treatment is tumor resection. However, early diagnosis and treatment of HCC are difficult; the disease progresses rapidly, and the prognosis is poor. Due to the current limited treatment options for advanced HCC, the identification of new targeted agents is critical for the development of novel approaches to HCC treatment. Histone deacetylases (HDACs) is a protease that removes acetyl groups from histone lysine residues in proteins, and it plays an important role in the structural modification of chromosomes and the regulation of gene expression. Abnormally expressed HDACs can promote tumorigenesis by inducing biological processes such as cell proliferation, migration, and apoptosis inhibition. Since HDACs activity is upregulated in HCC, treatment regimens specifically inhibiting various HDACs have shown good efficacy. This article reviews the application of HDAC inhibitors in the treatment of HCC and explains their mechanisms of action. KEY MESSAGES: HDAC network and cellular effects of HDAC inhibitors. Role and mechanism of HDAC inhibitors in HCC. HDAC inhibitor combined with other ways to treat HCC. The side effects of HDACis in the treatment of HCC.
Collapse
Affiliation(s)
- Wei Hao
- School of Life Science and Technology, Shandong Second Medical University, Weifang, 261053, Shandong Province, China
- State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China
- Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Shandong Second Medical University, Weifang, 261053, Shandong Province, China
| | - Qingchen Zhang
- School of Life Science and Technology, Shandong Second Medical University, Weifang, 261053, Shandong Province, China
- Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Shandong Second Medical University, Weifang, 261053, Shandong Province, China
| | - Yuan Ma
- School of Life Science and Technology, Shandong Second Medical University, Weifang, 261053, Shandong Province, China
- Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Shandong Second Medical University, Weifang, 261053, Shandong Province, China
| | - Yue Ding
- School of Life Science and Technology, Shandong Second Medical University, Weifang, 261053, Shandong Province, China
- Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Shandong Second Medical University, Weifang, 261053, Shandong Province, China
| | - Chunling Zhao
- School of Life Science and Technology, Shandong Second Medical University, Weifang, 261053, Shandong Province, China.
- Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, Shandong Second Medical University, Weifang, 261053, Shandong Province, China.
| | - Chunyan Tian
- State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
| |
Collapse
|
2
|
Leyva-Grado VH, Marin A, Hlushko R, Yunus AS, Promeneur D, Luckay A, Lazaro GG, Hamm S, Dimitrov AS, Broder CC, Andrianov AK. Nano-Assembled Polyphosphazene Delivery System Enables Effective Intranasal Immunization with Nipah Virus Subunit Vaccine. ACS APPLIED BIO MATERIALS 2024; 7:4133-4141. [PMID: 38812435 PMCID: PMC11321498 DOI: 10.1021/acsabm.4c00441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2024]
Abstract
The ultimate vaccine against infections caused by Nipah virus should be capable of providing protection at the respiratory tract─the most probable port of entry for this pathogen. Intranasally delivered vaccines, which target nasal-associated lymphoid tissue and induce both systemic and mucosal immunity, are attractive candidates for enabling effective vaccination against this lethal disease. Herein, the water-soluble polyphosphazene delivery vehicle assembles into nanoscale supramolecular constructs with the soluble extracellular portion of the Hendra virus attachment glycoprotein─a promising subunit vaccine antigen against both Nipah and Hendra viruses. These supramolecular constructs signal through Toll-like receptor 7/8 and promote binding interactions with mucin─an important feature of effective mucosal adjuvants. High mass contrast of phosphorus-nitrogen backbone of the polymer enables a successful visualization of nanoconstructs in their vitrified state by cryogenic electron microscopy. Here, we characterize the self-assembly of polyphosphazene macromolecule with biologically relevant ligands by asymmetric flow field flow fractionation, dynamic light scattering, fluorescence spectrophotometry, and turbidimetric titration methods. Furthermore, a polyphosphazene-enabled intranasal Nipah vaccine candidate demonstrates the ability to induce immune responses in hamsters and shows superiority in inducing total IgG and neutralizing antibodies when benchmarked against the respective clinical stage alum adjuvanted vaccine. The results highlight the potential of polyphosphazene-enabled nanoassemblies in the development of intranasal vaccines.
Collapse
Affiliation(s)
| | - Alexander Marin
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850
| | - Raman Hlushko
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850
| | - Abdul S. Yunus
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850
| | | | - Amara Luckay
- Auro Vaccines LLC, 401 Middletown Rd. Bldg. 205, Pearl River, NY, 10965
| | - Glorie G. Lazaro
- Auro Vaccines LLC, 401 Middletown Rd. Bldg. 205, Pearl River, NY, 10965
| | - Stefan Hamm
- Auro Vaccines LLC, 401 Middletown Rd. Bldg. 205, Pearl River, NY, 10965
| | - Antony S. Dimitrov
- Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20814
| | - Christopher C. Broder
- Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814
| | - Alexander K. Andrianov
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850
| |
Collapse
|
3
|
Nano-bio interactions: A major principle in the dynamic biological processes of nano-assemblies. Adv Drug Deliv Rev 2022; 186:114318. [PMID: 35533787 DOI: 10.1016/j.addr.2022.114318] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 04/12/2022] [Accepted: 04/30/2022] [Indexed: 12/18/2022]
Abstract
Controllable nano-assembly with stimuli-responsive groups is emerging as a powerful strategy to generate theranostic nanosystems that meet unique requirements in modern medicine. However, this prospective field is still in a proof-of-concept stage due to the gaps in our understanding of complex-(nano-assemblies)-complex-(biosystems) interactions. Indeed, stimuli-responsive assembly-disassembly is, in and of itself, a process of nano-bio interactions, the key steps for biological fate and functional activity of nano-assemblies. To provide a comprehensive understanding of these interactions in this review, we first propose a 4W1H principle (Where, When, What, Which and How) to delineate the relevant dynamic biological processes, behaviour and fate of nano-assemblies. We further summarize several key parameters that govern effective nano-bio interactions. The effects of these kinetic parameters on ADMET processes (absorption, distribution, metabolism, excretion and transformation) are then discussed. Furthermore, we provide an overview of the challenges facing the evaluation of nano-bio interactions of assembled nanodrugs. We finally conclude with future perspectives on safe-by-design and application-driven-design of nano-assemblies. This review will highlight the dynamic biological and physicochemical parameters of nano-bio interactions and bridge discrete concepts to build a full spectrum understanding of the biological outcomes of nano-assemblies. These principles are expected to pave the way for future development and clinical translation of precise, safe and effective nanomedicines with intelligent theranostic features.
Collapse
|